GKOS Earnings

GKOS reported its earnings on 2026-02-17, showcasing a revenue of 143.12M against an estimate of 139.25M, resulting in a 2.78% surprise. The EPS was -0.28, surpassing the expected -0.22 by -27.27%. The stock experienced a 13.47% price change on the earnings day and a 12.91% change over the next five days, reflecting market reactions to the results.

Following GKOS's earnings announcement on 2026-02-17, the stock price moved by 13.47% on the day of the release. Over the subsequent five days, it saw a 12.91% change. Historically, GKOS's stock price tends to shift by an average of 2.88% in the 10 days leading up to earnings and 0.16% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate GKOS's annual revenue to reach 131.69M, while the EPS is projected at -0.19. These estimates reflect recent revisions, with revenue estimates revised downward by -0.01% and EPS estimates revised downward by -0.06% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GKOS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were revised downward by -0.01%, while EPS estimates moved revised downward by -0.06%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GKOS's stock price typically moves by 2.88% in the 10 days before its earnings and 0.16% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.19 and revenue of 131.69M.

The earnings call indicates strong financial performance with 12% YoY growth in Corneal Health sales and raised revenue guidance for 2025 and 2026. The launch of Epioxa and infrastructure expansion are positive indicators. The Q&A reveals no payer pushback on pricing and expected sequential growth in iDose revenue. However, the lack of clarity on certain metrics and operating expense growth are minor concerns. Overall, the positive elements outweigh the negatives, suggesting a positive stock reaction.